Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide

Q J Nucl Med Mol Imaging. 2004 Sep;48(3):220-8.


Aim: In a previous phase I-II study, the safety profile and anti-tumor efficacy of pre-targeting locoregional radioimmunotherapy (LR-RIT), based on the ''3 step'' method, was assessed in 24 high-grade glioma patients. The encouraging results in terms of low toxicity and objective response rate (25%) prompted us to continue our study.

Methods: An analysis of 73 patients with hystologically confirmed glioblastoma multiforme (GBM), treated with the ''3 step'' (90)Y-biotin based LR-RIT, is herein reported. All patients had a catheter implanted at 2(nd) surgery and underwent at least 2 cycles of LR-RIT (range 2-7) with 2 months interval. Thirty-five out of 73 patients were also treated with Temozolomide (TMZ). Two cycles of TMZ (200 mg/m(2)/day, for 5/28 days) were administered in between each course of LR-RIT. Overall survival (OS) and progression free survival (PFS) were retrospectively calculated.

Results: Stabilization of disease was achieved in 75% of patients, while 25% progressed. In the 38 patients treated with LR-RIT alone, median OS and PFS were respectively 17.5 months (95%CI=[17-20]) and 5 months (95%CI=[4-8]), while in the 35 treated with the combined treatment (LR-RIT+TMZ) respective values were 25 months (95%CI=[23-30]) and 10 months (95%CI=[9-18] (p<0.01). The addition of TMZ to LR-RIT did not increase neurological toxicity, and no major hematological toxicity was observed.

Conclusion: These results confirm the safety and the efficacy of (90)Y LR-RIT in recurrent GBM patients; the addition of TMZ significantly improved the overall outcomes; a further controlled prospective, randomized study is fully justified.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Antineoplastic Agents, Alkylating / administration & dosage
  • Biotin / therapeutic use*
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / mortality
  • Brain Neoplasms / radiotherapy*
  • Chemotherapy, Adjuvant / methods
  • Combined Modality Therapy
  • Dacarbazine / administration & dosage*
  • Dacarbazine / analogs & derivatives*
  • Disease-Free Survival
  • Drug Delivery Systems / methods
  • Female
  • Glioblastoma / diagnosis
  • Glioblastoma / drug therapy*
  • Glioblastoma / mortality
  • Glioblastoma / radiotherapy*
  • Humans
  • Italy / epidemiology
  • Male
  • Middle Aged
  • Radioimmunotherapy / methods
  • Radiopharmaceuticals / therapeutic use
  • Survival Analysis
  • Temozolomide
  • Treatment Outcome
  • Yttrium Radioisotopes / therapeutic use*


  • Antineoplastic Agents, Alkylating
  • Radiopharmaceuticals
  • Yttrium Radioisotopes
  • Biotin
  • Dacarbazine
  • Temozolomide